stockportfolio.pro
Stocks / LMAT vs RARE
LMAT vs RARE
LeMaitre Vascular, Inc. and Ultragenyx Pharmaceutical Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| LeMaitre Vascular, Inc. (LMAT) | Ultragenyx Pharmaceutical Inc. (RARE) | |
|---|---|---|
| Market cap | $2.1B | $2.3B |
| Revenue (latest FY) | $249.60M | $673.00M |
| Net income (latest FY) | $57.73M | $-575.00M |
| Revenue growth (5y CAGR) | 14.0% | 19.9% |
| Net margin | 23.1% | -85.4% |
| Return on equity | 14.7% | 718.8% |
| P/E ratio | 34.1 | — |
| Dividend yield | 1.0% | — |
| Profitable years (of last 10) | 10 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open LMAT — free Open RARE — freeFrequently asked questions
Which is bigger, LMAT or RARE?
Ultragenyx Pharmaceutical Inc. is larger by market capitalization — $2.3B versus $2.1B.
Which grows faster, LMAT or RARE?
Over the last five fiscal years, Ultragenyx Pharmaceutical Inc. grew revenue faster — 19.9%/yr versus 14.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.